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GENERAL INTRODUCTION 
Brucella abortus is the causative agent of bovine brucellosis, a 
disease that causes spontaneous abortion in cows. The most effective 
and cost effective form of protection against this pathogen is 
immunization; however, Brucella abortus strain 19 (the standard 
vaccine against Brucella abortus) is not completely protective. The 
work described in this thesis details the vaccination of laboratory 
mice with the heat shock protein, hsp60 derived from Brucella abortus, 
using live attenuated recombinant Salmonella typhimurlum expressing 
hsp60 as a delivery system, and the characterization of the immune 
response to Brucella abortus hsp60 over a 12 week time course 
following vaccination. The scientific studies described can be broadly 
divided into 4 main sections, as follows: 
1. Identification, cloning, and characterization of the Brucella 
abortus-hsp60 (B-hsp60) gene. 
2. Construction of plasmids expressing the Brucella abortus-
hsp60 gene constitutively, and the characterization of that expression 
\n Salmonella typhimurlum x4064 strains transformed with such B-
hsp60 expressing plasmids. 
3. Assessment of appropriate delivery of B-hsp60 to the immune 
system of BALB/c mice by various recombinant Salmonella 
typhimurlum x4064 strains expressing graded quantities of B-hsp60, 
by measuring humoral antibody titers against B-hsp60, as well as T-
cell blastogenic responses to B-hsp60, in response to in vitro 
stimulation with B-hsp60. 
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4). Evaluation of T-cell effector functions late in the course of a 
primary recombinant Salmonella typhimurium x4064 infection, by 
monitoring the production and secretion of the cytokines, interferon-
gamma (IFN-y), lnterleukin-4 (IL-4), and lnterleukin-10 (IL-10), in 
response to in wtro stimulation of splenocytes from recombinant 
x4064 infected mice with purified B-hsp60 protein, and demonstration 
of cytolytic activity , specific for, and directed against B-hsp60 pulsed 
target cells. 
Literature survey 
Brucella abortus is the causative agent of bovine brucellosis, a 
disease which mainly affects cattle, causing abortion and infertility in 
these animals [1 ]. Humans that come in contact with infected animals, 
or contaminated products thereof may become infected, acquiring a 
debilitating disease which oftentimes becomes chronic, despite 
protracted antibiotic treatment. Other closely related Brucella species 
cause disease in goats, sheep, swine, dogs, and numerous other 
mammals [2]. Brucella abortus has worldwide distribution [3], and 
despite an active vaccination program, it is still economically 
important and prevalent in parts of the United States [4,5]. 
Brucella exists in the host animal primarily as an intracellular 
parasite [6,7] which, like other intra-cellular bacterial parasites such 
as Mycobacterium, Salmonella, and Listeria [8], is able to survive and 
replicate within phagocytic cells of the host's reticulo-endothelial 
system [9]. Late in the infection, the brucellae are sequestered in 
granulomas (focal aggregations of infected mononuclear phagocytes. 
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surrounded by sensitized T lymphocytes) wherein the bacteria are 
slowly killed [6,10]. In pregnant ruminants, brucellosis is characterized 
by infection of placental tissues, where the bacteria are preferentially 
localized within trophoblasts of the placenta [11,12]. In chronic bovine 
brucellosis, brucellae are found within macrophages of the mammary 
gland, where they may persist for the life of the cow, continually 
shedding organisms into the milk [1,14]. Vaccination remains the best 
form of protection against such pathogens, and such prophylactic 
measures have taken on new significance in the light of recent reports 
documenting the increasing occurrence of multiple drug resistant 
strains of bacterial pathogens [15], and a general resurgence of 
infectious diseases that have come about, mainly as opportunistic 
infections afflicting individuals whose immune system has been 
compromised, as seen in people infected with human immuno­
deficiency virus (HIV) [16]. 
Over the years, there have been attempts made to develop 
vaccines with improved efficacy against 6rt/ce//a abortus. To that end, 
live reduced dose vaccines [17,19,24], non viable whole cell vaccines 
[21-24], outer envelope fractions [25,26], cell free detergent extracts 
[22-24,27], phenol extracts [18,28], ribosomal preparations [29], 
lipopolysaccharides [30-34], and purified proteins [25,32,34,35] have 
been prepared. Of all these vaccine formulations tested, the most ef­
fective have been the attenuated live derivatives of the parent 
bacterium against which protective immunity is desired. Such attenu­
ated strains are able to survive within the host for some time and to 
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express bacterial immunogens for presentation to the host's immune 
system [36-42], but do not cause serious disease [43]. There is no 
explanation as to why the generation of protective immunity against 
intracellular pathogens requires a live infection, but it has been 
hypothesized that such immunogens as are transported, or leak out 
from actively dividing bacteria within the phagosome are taken up by 
the phagocytes and processed for antigen presentation [44]. This 
obviates the need for protein antigens to be expressed on the bacterial 
surface, and explains the reactivity of sensitized T lymphocytes from 
infected animals to numerous cytosolic bacterial proteins [44]. The 
standard vaccine against bovine brucellosis is the live attenuated 
strain, Smce//a abortus strain 19 [45]. To date, no suitable vaccine 
exists for humans. 
There are two main problems associated with attenuated live 
vaccines, such as B. abortus strain 19: The first is the inability of 
health care/surveillance workers to distinguish between the 
immunological signatures of healthy vaccinated individuals and 
individuals infected with virulent strains of the same species [46,47]; 
and the second is that these vaccines do not adequately protect 
vaccinates [45,48]. 
Most of the information on acquired immunity to Brucella abortus 
has been obtained from experiments carried out in laboratory mice. 
When BALB/c strain of laboratory mice are infected intravenously with 
Brucella abortus strain 19, the organism replicates to large numbers 
in the spleen and reaches peak concentrations at 2 weeks post infection 
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(p.i.)» followed by progressive clearance, such that the infection is 
cleared by about 8 weeks p.i. In contrast, infection of this same strain 
of mice with the virulent Brucella abortus strain 2308 produces a 
protracted infection without overt disease [25], which corresponds to 
brucellosis in cattle. 
Despite a large body of literature available on the immunology of 
brucellosis, there is still no clear understanding of how the organism 
manages to evade/withstand the host's immune response. Brucellae are 
very resistant to direct killing by immune serum [49,50]. Macrophages 
from non-immune animals readily ingest brucellae, but the ingested 
organisms actively proliferate within these cells [51-54]. Neutrophils 
are capable of killing ingested brucellae, but do so slowly [55-57]. 
Experiments involving adoptive transfer of serum, or of various 
lymphocyte fractions from experimentally infected mice to naive mice 
have demonstrated that acquired immunity to B. abortus is mediated by 
cell-mediated immune responses [58,90], and to a lesser extent, 
humoral immune responses [90,91 ]. The protective effects of immune 
serum have been shown to be partly due to antibodies directed against 
the 0-polysaccharide component of B. abortus LPS [61 ], and as such are 
thought to be effective only against secondary infections with Brucella. 
Studies carried out in vitro indicate that macrophages and immune T-
cells can kill Brucella [53,54], and this bactericidal activity is 
enhanced in the presence of immune serum [51,53]. It is generally 
accepted that part of the cell-mediated immune response involves 
antigen specific T lymphocytes, which in response to bacterial antigens 
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secrete a variety of lymphol<ines, wliich in turn stimulate and enhance 
bactericidal mechanisms of phagocytes, thereby leading to killing of 
the ingested organisms [62-64]. In mice, CD 4+ T lymphocytes have been 
divided into two major subsets on the basis of non-overlapping 
profiles of lymphokines secreted after appropriate stimulation with 
antigens, or mitogens such as Concanavalin A [65]; thus TH1 
lymphocytes typically secrete interleukin-2 (IL-2), and interferon 
gamma (IFN-y), and are believed to be responsible for delayed type 
hypersensitivity (DTH) [66,67], while TH2 lymphocytes typically 
secrete IL-4, IL-5, and IL-10 [68], and are responsible for the helper 
function in antibody production by B-lymphocytes. IFN-y is capable of 
activating three major pathways described for microbial killing, which 
are; the production of reactive oxygen intermediates [69], the 
production of reactive nitrogen intermediates [70], and the induction of 
2,3 dioxygenase to catabolize tryptophan [71 ]. Current data suggests 
that a TH1 type T-cell response is required for bacterial killing and 
clearance of a Brucella infection [66,72], and consistent with this, 
IFN-y, together with IL -2 are capable of mediating enhanced killing of 
brucellae when added to infected macrophages in vitro [73], and 
injection of recombinant IFN-y into mice enhances resistance to 
Brucella [76], and other intracellular parasites [75], whereas injection 
of antibody to IFN-y exacerbates infection with these intracellular 
parasites [74]. 
Experimental infection of mice with various intracellular 
microorganisms has revealed an additional cell mediated mechanism. 
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which involves the lysis of infected target macrophages by T-cells 
belonging to different subsets: Thus Major Histocompatibility Complex 
(MHC) class II restricted T-cells that mediate lysis of Listeria 
infected macrophages [114, 115], CD4+ T cells that mediate cytolysis 
of Mycobacterium infected macrophages [44], and CD8+ T cells that 
mediate lysis of Salmonella infected cells [116], have all been 
demonstrated in BALB/c mice. It has been hypothesized that such 
subsets of cytolytic T-cells play an important role in the eventual 
clearance of intracellular microorganisms by lysing chronically 
constipated infected macrophages that have been rendered anergic, to 
release their content of microorganisms, which can be then be 
effectively eliminated by fresh phagocytes, or by humoral bactericidal 
mechanisms [114]. At present, this hypothesis is backed only by 
circumstantial evidence, and the requirement for antigen specific 
cytolytic T-cells as part of a protective immune response has not been 
conclusively demonstrated. 
Brucella abortus acx\ye\y modulates selected phagocyte 
responses. Whereas macrophages containing brucellae appear activated 
by certain criteria, such as random locomotion, increased Fc receptors, 
and generalized phagocytic activity [77], there is an inhibition of 
phagosome-lysosome fusion, and a decreased oxidative burst 
associated with bacterial ingestion [78]. This inhibition has been 
partially accounted for in neutrophils, where the ingested brucellae 
apparently secrete adenine, and 5'-guanosine monophosphate, which 
inhibit degranulation of primary granules, resulting in decreased 
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myeloperoxidase dependent oxidative attack [79-81 ]. Brucella LPS has 
been shown to decrease the surface-bound expression of IL-1 on 
macrophages in the presence of IFN-y, leading to a decreased ability to 
stimulate proliferation of T cells [85,86]. 
It is well established that macrophages infected with bacteria 
secrete increased amounts of prostaglandin E2 (PGE2) [82,84]. PGE2 has 
a direct down-regulatory effect on the activated state of macrophages, 
and in addition, selectively inhibits production of TH1 lymphokines [83] 
resulting in a further dampening of the protective infection clearing 
response, and promotes the establishment of conditions that favor 
chronic infection [84]. Thus, treatment of Brucella infected mice with 
indomethacin (a potent inhibitor of PGEz synthesis) results in enhanced 
clearance of the bacteria, compared to untreated mice [76]. 
The protective roles of various T-cell subtypes during Brucella 
infection are not well characterized, but it is known that double 
negative, CD4" CD8" T cells have no ability to confer immunity in cell 
transfer experiments [90], whereas both CD4+, and CD8+ T cells 
contribute to protective immunity in similar types of adoptive transfer 
experiments [90,91 ]. Purified CD4+ and CD8+ T cells from Brucella 
infected mice have recently been shown to secrete IFN-y in response to 
stimulation with purified Brucella protein antigens in vitro [87]. 
However, it must be noted that the Brucella antigens used above were 
most likely contaminated with smooth Brucella LPS which may have 
confounded the reported results. LPS is the dominant humoral antigen 
during the course of Brucella infection and, due to its stickiness, also 
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contaminates all protein/antigen preparations derived from smooth 
Brucella strains [23, 33, 59]. Brucella LPS is a potent immunogen, and 
has been shown by itself to stimulate IFN-y production from human 
CD4+ and CD8+ T cells [88,89]. This contrasts to LPS's of enteric 
bacteria, such as E. coll, and S. typhlmurium, which do not stimulate 
IFN-y production (this study). There is a fair amount of circumstantial 
evidence that supports the hypothesis that a switch in T cell type 
occurs during the course of a Brucella infection, from a TH1 type T-
cell response associated with a bactericidal stage early, to a TH2 type 
T-cell response later on, characterized by increasing amounts of 
circulating antibody and immune T cells, and the persistence of large 
numbers of bacteria associated with suppression of macrophage 
bactericidal activity [84,90,92,93]. A similar pattern as has been 
demonstrated for experimental syphilis [84]. 
It can be seen from this brief overview that interactions between 
brucellae and their hosts are extremely complex; brucellae have 
evolved a multifaceted strategy for survival within the host, which 
includes resistance to killing by humoral factors, evasion of phagocyte 
killing mechanisms, and active downregulation of an aggressive 
immune response. 
In order to design new vaccines, a better understanding is needed 
of the antigens capable of eliciting a protective response to infection 
with the intact organism. To date, there is no clear picture of what 
antigens evoke a protective immune response in brucellosis, because 
most of the work done to characterize the immunogenicity of Brucella 
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antigens utilized antigens prepared from smooth strains of the 
organism, and therefore suffered from the drawback of contamination 
of the proteins with LPS [60]. LPS is the major humoral antigen during a 
Brucella infection [59,60], and is capable of modifying, or masking 
immune responses to other antigens which may be present [32,35]. 
Research plan 
In order design subunit vaccines, it is necessary to accurately 
assess the immunogenicity of individual proteins, separating the 
protein of interest from the rest of the pathogen from which it is 
derived. 
The starting point for this work was to screen a genomic library 
for the gene encoding the protein of interest. The Brucella analog of 
hsp60 (B-hsp60), was chosen as a suitable test antigen in this study, 
because members of the heat shock protein family had been shown to 
stimulate strong cellular, and humoral immune responses during the 
course of mycobacterial, salmonella, and borrelia infection in mice 
[94]. Owing to the high degree of conservation of hsps from 
evolutionarily distant organisms, it was judged reasonable to expect B-
hsp60, also to be a good cellular and humoral immunogen. Oral infection 
with live recombinant attenuated Salmonella typhimurium expressing 
the B-hsp60 gene was chosen as the delivery system for presentation 
of B-hsp60 to the immune system for several reasons; it {Salmonella 
typhimurium) provides long term exposure to the antigen, localizes the 
antigen to lymph nodes and spleen, and presents the antigen in a 
bacterial context, but decoupled from other possible modulatory 
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activities of Brucella . Also, vaccination with recombinant Salmonella 
has been shown to stimulate humoral, secretory, and cellular immunity 
directed against foreign antigens expressed within them [36-42,117]. 
One of the more practical objectives of this study was to critically 
evaluate the protective potential of immunization with a single antigen 
(in this case B-hsp60) against subsequent infection with the virulent 
parent organism (Brucella abortus). Using attenuated Salmonella as 
the delivery system had an additional advantage which was exploited in 
attempting to evaluate the protective potential of vaccination with B-
hsp60, which is as follows: Previous infection of BALB/c mice with 
Salmonella typhimurium x4064 (used in this study) protects such 
mice from a subsequent lethal challenge infection with virulent 
Salmonella typhimurium [117]. It was therefore hypothesized that the 
quality of the immune response generated against this Salmonella 
carrier would be indicative of a protective immune response, and 
because Salmonella, (like Brucella ) is a bonafide intracellular 
pathogen, that the production of an immune response against B-hsp60 
during the course of the recombinant Salmonella infection that was 
qualitatively similar to that elicited against Salmonella itself might 
allow a more objective assessment of the protective potential of such 
a single subunit vaccination scheme. Salmonella typhimurium x4064 
therefore served the function of a positive, and internal control, versus 
which to compare immune responses against B-hsp60. 
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MATERIALS AND METHODS 
Identification, cloning, and sequencing of the Brucella 
abortus groEopevon 
Clones containing Brucella abortus gro E gene sequences were 
positively selected by a low stringency hybridization, using the 
Escherichia coll gro EL gene (kindly provided by Costa Georgopoulos, 
University of Utah School of Medicine) [95] to probe a Brucella abortus 
strain 19 genomic DNA library, by plaque hybridization, as described 
[96]. Briefly, plaques from the Brucella abortus genomic library in 
bacteriophage lambda 1059 [97] were produced on a lawn of E coli 
Q359 at a density of approximately 500 per 90 cm2 plate, and 
transferred directly to nitrocellulose filter paper. The bound DNA was 
denatured in 0.1 N NaOH, 1M NaCI and hybridization was conducted using 
5x106 cpm. of 32p labeled plasmid pBS, containing E. coll gro EL DNA 
as a probe. The probe DNA was labeled by nick translation [98], in 
hybridization solution containing 6x saline sodium citrate (SSC), 0.25% 
nonfat dried milk, and 1% NP40 detergent, and either 0%, 25%, or 50% 
formamide, at 42°C for 24 hours. The filters were washed and exposed 
to X-ray film. Hybridization with 25% formamide appeared to 
discriminate positive from negative plaques. Positively hybridizing 
plaques obtained under optimal hybridization conditions (i.e. 
hybridization solution containing 25% formamide) were rescreened as 
described above, and DNA prepared from these plaques [99]. The 
Southern blot technique was used to identify appropriate DNA 
fragments that contained the Brucella gro E operon [100], which were 
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then sub cloned into pUCl 18 and pUCI 19 plasmid vectors [101]. 
Plasmids pBHS60-6-E-9 and pBHS-4-H-9 were used as the 
experimental material for sequencing by the chain termination method 
[102]. 
Purification of Brucella abortus hsp60 protein (B-hsp60) 
The entire Sruce/Za abo/tt/s fifro EL gene was cloned into a 
regulatable high expression plasmid vector called pJE-7. This plasmid 
features the pKK 223-3 derived tac (tryptophan/lactose hybrid) 
promoter [103] to drive high expression of an appropriately cloned gene 
construct. The 8 kilobase long EcoRI fragment from plasmid pBHS60-6-
E-9 was ligated into pJE-7 at the EcoRI site. The resultant plasmid was 
named pDG-7. For purification of B-hsp60 protein, £ co//TG-1 (pDG-7), 
(the E. coli clone expressing Brucella hsp60), was grown to mid-log 
phase in Luria-Bertani (LB) broth [13] containing 75 micrograms per 
mL ampicillin, and protein expression induced with Isopropyl p, D-
thiogalactoside (IPTG) [104] for 6 hours in a final concentration of 200 
mg/mL ampicillin, to ensure plasmid retention. The bacteria were 
washed and resuspended in buffer containing 50 mM Tris (pH 8.0), 5 mM 
EDTA, 10 mM PMSF (TEP), and disrupted by lysozyme treatment and 
sonication, as described [105]. The resulting lysate was subjected to 
centrifugation at 100,000 x g for 1.5 hours, the supernatant loaded 
onto a DEAE sepharose column equilibriated in TEP, and protein 
fractions eluted with a continuous gradient of 0-0.5 M NaCI in TEP. An 
elution profile was determined spectrophotometrically at 280 
nanometers, and fractions enriched for B-hsp60 (identified by heavy 
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staining in coomassie blue stained Laemmli gels [107]) were pooled and 
used for preparative gel electroplioresis, followed by electroelution of 
the desired protein band [106]. This purified protein was emulsified in 
Freunds incomplete adjuvant and injected subcutaneously into rabbits 
to prepare anti B-hsp60 serum [108]. The antiserum obtained after one 
priming and one booster injection was subsequently used for 
monitoring the large scale purification of B-hsp60 by western blot 
[109]. Purification of milligram quantities of B-hsp60 was effected as 
described above, with the exception that B-hsp60 enriched fractions 
were subjected to an additional round of ion exchange chromatography 
on DEAE sepharose, in place of preparative gel electrophoresis as the 
final purification step. The purified protein was stored at -70°C until 
further use. In later preparations, substitution of Tris buffer with 
sodium phosphate buffer at 50 mM was found to greatly reduce the 
degradation of the protein during purification. 
Construction of plasmids expressing B-hsp60 constitutively 
A 2.5 kilobase long BamHI/EcoRI DNA fragment (derived from 
pBHS60-6-E-9) that contained the B-hsp60 gene was cloned into a 
series of plasmid expression vectors in E coliTGI host cells using 
standard molecular cloning techniques [115]. These plasmid vectors 
(named pJE-3 through pJE-6 [110]) all contain the ampicillin resistance 
[p lactamase] gene as well as constitutive promoters of differing 
strengths, that can direct the expression of appropriately cloned genes. 
The resulting plasmids were named pDG-3, pDG-4, pDG-5, and pDG-6. 
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Plasmid pDG-3 directs high expression, pDG-4 & pDG-5 moderate 
expression, and pDG-6 low expression, of the B-hsp60 gene. 
Construction of recombinant 5. typhimurium x40Q4 (B-hsp60) 
expression vectors 
In order to overcome restriction barriers that prevent the 
efficient transfer of DNA from one bacterial species to another, the 
pDG plasmids which were cloned in E. coli (described above) were first 
introduced into a restriction negative, modification positive, rough 
Salmonella typhimurium strain SL5283 by the method of Lederberg and 
Cohen [111]. Plasmid DNA was prepared from these intermediate 
recipients by the all<aline lysis method [113], and subsequently 
introduced into an avirulent nalidixic acid reslstantSalmonella 
typhimurium SR 11 double deletion (Acya/Acrp) mutant S. typhimurium 
x4064 (kindly provided by R. Curtiss III, Washington University, St. 
Louis, MO) by electroporation [112], Accumulation of B-hsp60 protein in 
the various recombinant ^4064 strains was characterized by western 
blot [109] after electrophoresing total bacterial cell lysates into 11% 
SDS-polyacrylamide gels [107]. 
Preparation of S. typhimurium 5c4064 (pJE-3) soluble antigen 
Soluble antigen for use in in vitro blastogenesis, and antibody 
titration was prepared by the method of Shaible et al. [52]. Briefly, S. 
typhimurium x40S4 (pJE-3) was grown for 24 hours in LB broth 
containing 100 mg/mL ampicillin, with shaking (250 rpm at 37°C). The 
cells were washed three times by repeated pelleting and resuspension 
in fresh 0.01 M phosphate buffered saline, pH 7.2 (PBS) and disrupted by 
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sonication (model Braunsonic 1510, from B. Braun Instruments, S. San 
Francisco, CA.) eight times in 15 second bursts at 4°C. The sonicate 
was centrifuged at 10,000 x g for 10 minutes, the supernatant 
recovered and filter sterilized through 0.22 p.m pore size filters. This 
preparation is called S. typhimurium %4064 (pJE-3) or x4064 S.A. 
throughout this thesis. 
Animals 
All vaccination experiments described below were performed 
with specific pathogen free laboratory mice aged 10 to 12 weeks at the 
start of each experiment. The mice were housed in the Laboratory 
Animal Resource Facility at the College of Veterinary Medicine, Iowa 
State University, and given sterile food and water ad libitum. 
Infection (vaccination) of mice with recombinant strains of 
Salmonella typhimurium x4064 
BALB/cByJ strain of laboratory mice (Jackson Laboratories, Bar 
Harbor, ME) were vaccinated with different recombinant strains of 
Salmonella typhimurium %4064 (i.e. x4064 (pJE-3), %4064 (pDG-3), 
x4064 (DG-4), and x4064 (DG-6) intra esophageally using an intubation 
needle (1-inch 21 gauge from Popper and Sons, Inc., New Hyde Park, NY), 
as described previously[40]. Log phase bacterial suspensions were 
prepared by first inoculating 5 mL of LB broth containing 75 |ig per mL 
with each x4064 strain and incubating the cultures overnight. These 
overnight cultures were diluted 20 fold in LB broth containing 75 |xg per 
mL, and grown for 4 hours at 37°C with shaking (250 rpm) to achieve 
log phase growth. The log phase x4064 cultures were pelleted and 
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resuspended in 0.01 M phosphate buffered saline (PBS) at 1/50th the log 
phase culture volume and stored on ice. Prior to intubation, stomach 
acidity of the mice was neutralized with 30 |j,L of 10% sodium 
bicarbonate administered orally, and the mice were immunized with 4 x 
108 recombinants, typ/j/mt/r/ty/77 x4064. The actual number of bacteria 
given was determined retrospectively, by standard plate counts of 
serial 10 fold dilution's on LB agar. At various time intervals after 
vaccination, groups of naive (control) and vaccinated mice were 
sacrificed. Following C02 asphixiation, blood was collected by heart 
puncture using 1 mL syringes and 22 gauge needles, and used to prepare 
serum. 
Bacterial loads The load of 5. typhimurium in the small 
intestine, mesenteric lymph nodes, spleens, and livers, of vaccinated 
mice were determined as follows: The organs were aseptically excised 
from euthanized mice and suspended individually in sterile Whirl-Pak 
bags (Nasco, Fort Atkinson, Wl) containing 0.85% saline. The organs 
were homogenized using a Stomacher 80 Laboratory Blender (A.J. 
Stewart, London), and bacterial counts obtained by plating the 
homogenates on MacConkeys agar containing nalidixic acid [43]. S. 
typhimurium cells recovered from mice in this fashion were also 
tested for the retention of plasmids expressing B-hsp60, by sub-
culturing the salmonellae that grew on MacConkeys agar containing 
nalidixic acid onto LB agar containing 75 |ig/mL ampicillin. Only 
salmonellae that still retained the plasmids would be resistant to 
ampicillin. 
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Serum antibody responses Serum antibody responses of 
naive and vaccinated mice to B-hsp60 were determined by enzyme 
linl<ed immuno-sorbent assay (ELISA), as described [40]. Briefly, 96-
well Immulon 4 microtiter plates (Dynatech, Chantilly, VA.) were 
incubated overnight at 4°C with 1 iLig of either recombinant B-hsp60, 
x4064 SA diluted in 0.01 M PBS pH 7.2. All sera were diluted 1:10 in 
saline containing 0.05% Tween 20 (TS) prior to use. Total 
immunoglobulin was determined using alkaline phosphatase conjugated 
goat anti-mouse immunoglobulin G diluted 1:2000 in TS. Color was 
developed by addition of no. 104 phosphatase substrate (Sigma, St. 
Louis, MO), and absorbance read at 405 nanometers using an ELISA 
reader. 
Blastogenesis assays Antigen specific T-ceir proliferative 
responses to Brucella hsp60, and x4064 SA from spleens of vaccinated 
mice were performed as described [40]. Briefly, spleens were collected 
from groups of naive or vaccinated mice (n=3 or 4), homogenized with 
the stomacher to produce single cell suspensions, washed using RPMI 
and inoculated into 96 well culture clusters (2.5 x 10^ cells per well) 
containing one of the following: RPMI 1640 (Sigma), 0.5 mg per mL 
concanavalin A (Sigma, St. Louis, MO), 5 iig per mL E. coll LPS, B-hsp60 
at 0.2, 1, or 5 [ig per mL, or x4064 SA at 0.2, 1, or 5 |xg per mL. All cells 
were incubated for 5 days in RPMI 1640 containing 5% fetal bovine 
serum (Gibco-BRL), and 1% Serum Plus (Gibco-BRL). Cells were pulsed 
with [3h] thymidine for 12 hours prior to harvest, and counts were 
determined using a liquid scintillation counter (model 1500, Packard 
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Instrument Co., Inc., Downers Grove, IL). The results were calculated 
as stimulation indices for each mouse according to the general formula: 
Stimulation index = cpm experimental splenocytes (i.e. plus antigen) / 
cpm control splenocytes (i.e. medium only) 
Preparation of culture supernatants for the determination of 
secreted lymphokines 
Groups of mice were vaccinated with approximately 8 x 10^ of 
the following S. typhimurium strains: %4064 (pJE-3) (representing no 
B-hsp60 expressed); ^4064 (pDG-6) (representing low levels of B-
hsp60 expressed) x4064 (pDG-4) (representing moderate levels of B-
hsp60 expressed). Four mice from each treatment group, including a 
group of non-vaccinated mice, were sacrificed at days 34, 64 and 84, 
post infection, and single cell suspensions prepared from their spleens. 
Individual splenocyte preparations were washed in Dulbeccos Modified 
Eagles Medium (DMEM) (Gibco-BRL, Bethesda, MD), and resuspended in 
fresh DMEM supplemented with 10% fetal bovine serum (Gibco BRL, 
Bethesda, MD), and 50 mg per mL gentamicin (Gibco-BRL, Bethesda, MD), 
and seeded into 12 well culture dishes (Costar Corp., Cambridge, MA) at 
1 X 10^ cells per well, in a final volume of 2 mLs, together with one of 
the following; DMEM, purified B-hsp60 (10 fig per mL), or S. 
typhimurium x4064 (pJE-3) soluble antigen (10 ng per mL). Culture 
supernatants were harvested after 3 days (or 5 days, in the case of day 
84 post-infection splenocytes), filtered through 0.22 |j,m Vanex filters 
(Vangard Int'l., Inc., Neptune, NJ), and used to determine cytokine 
profiles, or stored at -70°C until needed. The supernatants were 
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analyzed for the cytokines IFN-y, IL-4, and IL-10, by sandwich enzyme 
linked immuno-sorbent assays (ELISAs), that utilized anti-mouse IFN-y, 
anti-mouse IL-4, and anti-mouse IL-10 immunoglogulins (Pharmingen, 
San Diego, CA), according to a protocol supplied by the manufacturer. In 
all cases, known concentrations of purified IFN-y, IL-4, and IL-IO 
(Genzyme Corp., Cambridge, MA) were Included in the ELISAs to provide 
a basis for quantitative estimates of the respective cytokines. 
Cytotoxicity assays 
For the purpose of measuring the ability of splenocytes from 
recombinant x4064 vaccinates to mediate lysis of antigen pulsed 
target cells, groups of mice were vaccinated with approximately 8 x 
108 of the following S. typhimurium strains: x4064 (pJE-3) 
(representing no B-hsp60 expressed); x4064 (pDG-6) (representing low 
levels of B-hsp60 expressed) x4064 (pDG-4) (representing moderate 
levels of B-hsp60 expressed). Four mice from each treatment group, 
including a group of non-vaccinated mice, were sacrificed at day 84, 
post Infection, and single cell suspensions prepared from their spleens. 
Individual splenocyte preparations were washed in Dulbeccos Modified 
Eagles Medium (DMEM) (GIbco-BRL, Bethesda, MD), and resuspended in 
fresh DMEM supplemented with 10% fetal bovine serum (Gibco BRL, 
Bethesda, MD), and 50 mg per mL gentamicin (Gibco-BRL, Bethesda, MD), 
and seeded Into 12 well culture dishes (Costar Corp., Cambridge, MA) at 
1 X 10^ cells per well, in a final volume of 2 mL together with one of 
the following: DMEM, purified B-hsp60 (10 iig per mL), or S. 
typhimurium x4064 (pJE-3) soluble antigen (10 )Lig per mL), to 
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stimulate generation of effector cytolytic lymphocyte populations. 
Splenocytes were harvested, and red blood corpuscles lysed by adding 6 
mL of distilled water to non-adherent splenocytes in 2 mL of DMEM for 
30 seconds, after which osmolarity was restored by adding 2 mL of 
3.5% NaCI solution. The splenocytes were washed by repeated pelleting 
and resuspension in DMEM. For use as effector cells in cytotoxic assays, 
pooled splenocytes representing each treatment group (i.e. x4064 (pJE-
3) vaccinated, B-hsp60 stimulated, or ^4064 SA stimulated, etc.) were 
pooled, and resuspended in DMEM plus 0,5% fetal bovine serum, at 4 x 
10® cells per mL, and added to 96 well round bottom plates that 
contained the BALB/c mouse-derived macrophage-like cell line, J774 
as target cells, in 0.5% fetal bovine serum, containing ^4064 (pJE-3) 
soluble antigen, or B-hsp60, at a final concentration of 20 |xg per mL, in 
a total volume of 200 [xL. Cytotoxicity was measured by the release 
into culture medium of the cytosolic enzyme, lactate dehydrogenase 
(LDH), using a non-radioactive cytotoxicity assay kit from Promega, 
according to a protocol supplied by the manufacturer (Promega, 
Madison, Wl), in a fashion analogous to the more widely used 51 Cr 
release assay. Percent cytotoxicity was quantitated for each 
splenocyte preparation as: 
TOO X ((experimental-effector spontaneous)-target spontaneous)/ 
(target maximum-target spontaneous). 
Flow cytometry 
In order to confirm that the LDH release assay was accurately 
measuring cytotoxicity, the mixtures of effector and target cells used 
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in the LDH release cytotoxicity assay described above were incubated 
further at 37^C, for a total of 72 hours. Total cells were harvested 
from individual wells, fixed in 2% paraformaldehyde, and analyzed 
using an Epics Profile Analyzer (Coulter Corp., USA). Cytotoxicity was 
estimated by the accumulation of dead cells in each experimental 
culture(J774 cells that are dead at the time of fixation are clearly 
distinguishable from J774 cells that are alive at the time of fixation, 
on the basis of forward scatter, as well as side scatter. These 
parameters were therefore taken advantage of in order to obtain counts 
of dead cells from each experimental culture. 
Statistical analysis 
Statistical analyses were performed using Students T tests. 
Differences were considered significant at p values of 0.05. 
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RESULTS 
Identification and cloning, and sequencing of the Brucella 
abortus gro E operon 
Identification of recombinant bacteriophage lambda plaques that 
contained the Brucella hsp60 gene was achieved using DNA 
hybridization conditions that allowed the radiolabelled E. coli hsp60 
gene DNA probe to preferentially detect high copy numbers of the 
Brucella hsp60 sequence with lower sequence homology, versus lower 
copy numbers of E. coli hsp60 DNA with TOO percent sequence homology. 
Five identical lambda clones containing B-hsp60 were identified in the 
initial plaque hybridization screen, and one of these plaques was 
selected and subcloned into pud 19 for further manipulation. 
Sequencing of the Brucella hsp60 gene was accomplished using 
appropriate sub-clones and oligonucleotide primers, by the chain 
termination method of Sanger et al [102]. An overview of the 
sequencing strategy is shown in Figure 1. 
Sequencing demonstrated that in Brucella, as in many other 
bacterial species, that the hsp60 gene sequence is preceded by the 
smaller hspl 0 gene sequence. Salient features of the Brucella gro E 
operon are 69% and 60% DNA sequence identity, and 68% and 50% 
predicted amino acid sequence identity, with the corresponding E. coli 
hsp60 (gro EL) and hspl 0 (gro ES) genes, respectively (the sequence [20] 
is shown in appendix 1). 
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groES groEL 
Figure 1. Sequencing overview of the Brucella gro E operon. Each arrow 
represents 2, and in most cases 3 independent sequencing runs. Open 
rectangles represent non coding regions, and filled rectangles represent 
coding sequences. 
Construction of recombinant S, typhimurium x^064 B-hsp60 
expression vectors 
A 2.5 kilobase long Eco Rl / Bam HI restriction digest DNA 
fragment containing the entire B-hsp60 gene, including its own Shine-
Dalgarno sequence (ribosome binding site), but not the B-hspTO 
sequence, was cloned into the plasmid expression vectors, pJE-3, pJE-
4, pJE-5, and pJE-6 (these plasmids have been described in detail in 
Emily Chin (1993), Ph.D. Thesis, Iowa State University), resulting in the 
corresponding plasmids, pDG-3, pDG-4, pDG-5, and pDG-6. Plasmid pDG-
3 was predicted to direct high expression, pDG-4 & 5 moderate 
expression, and pDG-6 low expression of the B-hsp60 gene. 
The expression of the B-hsp60 gene by the various plasmids was 
characterized by western blot of total bacterial lysates of recombinant 
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Figure 2. Western immunoblot of recombinant strains of E coli TGI 
(lanes A-E) and S. typhimurium x4064 (lanes F-J) showing relative 
accumulation of Brucella hsp60 protein. Bacterial strains containing 
either pJE-3 (E and J), pDG-3 (A and F), pDG-4 (B and G), pDG-5 (C and 
H), or pDG-6 (D and I) were grown to stationary phase in LB broth 
containing 100 mg/ml. ampicillin. Total lysates were first 
electrophoresed through an SDS, 11% polyacrylamide gel, and then 
transferred to nitrocellulose. Brucella hsp60 expression was detected 
using rabbit antiserum raised against B-hsp60 (see Materials and 
Methods). 
x4064 cells grown in LB medium for 24 hours, in the presence of 75 |ig 
per mL ampicillin (Figure 2). This western blot confirmed that the 
accumulation of B-hsp60 protein by the various engineered bacterial 
strains was accurately reflected by the relative rates of constitutive 
expression predicted for each pDG plasmid. It can be seen that the 
relative amounts of B-hsp60 accumulation for a particular pDG plasmid 
are similar between the £ coli and S. typhimurium bacterial strains, 
confirming that the rules that dictate efficiency of initiation are 
similar between E. coli and S. typhimurium . 
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Colonization of mice with recombinant S. typhimurium x4064 
Mice were orally infected (vaccinated) with strains ^4064 (pDG-
3), x4064 (pDG-4), and x4064 (pDG-6), as described in the Materials and 
Methods. At predetermined time intervals, mice were sacrificed and 
analyzed for various parameters of infection (Figure 3) and immune 
response. 
Following vaccination, the high B-hsp60 expressing S. 
typhimurium strain %4064 (pDG-3) lost the plasmid (pDG-3) expressing 
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Figure 3. Bacterial loads in S.typhimurium x4064 (pDG-6) infected 
mice. Mice were orally infected with 2 xl 0^ to 4 x10^ S. typhimurium 
x4064 (pDG-6). Mice were killed at intervals, and livers, spleens, small 
intestine, and mesenteric lymph nodes (MLN) were removed from each 
animal and homogenized. Viable counts of S. typhimurium x4064 (pDG-
6) were obtained by plating serial 10 fold dilution's of the homogenized 
organs on MacConkey agar plates containing 30 ^ig per mL of Nalidixic 
acid. Values reported are means of three mice per time point of one of 
two such experiments. 
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B-hsp60 within two days of their introduction into the mice (data not 
shown). These mice failed to produce detectable serum antibody 
responses to B-hsp60, a result that implies that strain x4064 (pDG-3) 
failed to deliver sufficient amounts B-hsp60 (figure 4). 
On the other hand, the B-hsp60 plasmids were stable in the 
moderate, and low B-hsp60 expressing strains of S. typhimurium , 
x4064 (pDG-4), and ^4064 (pDG-6), respectively. All subsequent work 
was therefore performed using these two bacterial strains . The extent 
of colonization of the various tissues of vaccinated mice (a typical 
time course of bacterial loads in the mice, following infection is 
shown in Figure 3) are similar to the results of Stabel et al. [40]. In all 
cases, bacteria were virtually undetectable in spleens, livers, 
mesenteric lymph nodes, and small intestines by 6 weeks post­
infection. 
Serum antibody responses 
Serum antibody titers against S. typhimurium x4064 (pJE-3) 
soluble antigens (x4064 S.A.) and B-hsp60 from mice infected with 
strains of recombinant S. typhimurium ^4064 did not begin to rise 
until approximately 4-5 weeks post-infection, and this observation 
was consistent for all the experiments performed (Figures 4-6). Strain 
DG-6 did not elicit significant immunoglobulin production against B-
hsp60, while the titers against %4064 SA, in the same mice were 
present, but only became significant 4 weeks post-infection (figure 6). 
This antibody response was specifically directed against B-hsp60 and 
not an S. typhimurium %4064 derived antigen because vaccination of 
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Figure 4. Antibody responses in reconnbinant Salmonella infected mice 
(mean + SEM, n=3). Mice infected with S. typhimurlum x4064 (pDG-3) 
were bled at intervals. The serum was assayed for antibodies against 
B-hsp60, or x4064 S.A. as described in Materials and Methods. 
mice with S. typhimurium x4064 (pJE-3) (this strain carries plasmid 
without the B-hsp60 gene), failed to elicit antibodies that cross-
reacted with B-hsp60 protein (see figure 7A). Mice infected with strain 
DG-4 showed high titers of antibody directed against B-hsp60 (Figure 
5, and 7A). 
The antibody responses against B-hsp60 in these experiments 
differ markedly from those reported for another Brucella abortus 
protein, BCSP31, when it was delivered to BALB/c mice in a similar 
type of experiment, using comparable numbers of recombinant S. 
typhimurium ^4064 [40]. In those experiments, antibody titers directed 
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Figure 5. Antibody responses (mean + SEM, n=3) in mice infected with 
recombinant S. typhimurium x4064 (pDG-4). Sera were assayed for 
antibodies against B-hsp60, or x4064 S.A. as described in Materials and 
Methods. Results are representative of two separate experiments. 
against BCSP31 began to rise by 2 weeks post infection, and reached a 
maximum by 4 weeks post infection. 
Blastogenic responses following immunization 
Splenocyte blastogenesis in response to in vitro stimulation with 
B-hsp60 protein was observed in vaccinates from the earliest time 
point that it was measured (14 days post infection )(Figure 8). The 
stimulation indices for splenocytes derived from mice vaccinated with 
x4064 (pDG-4) were consistently higher than the stimulation indices 
for splenocytes derived from x4064 (pDG-6) vaccinated mice in 
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Figure 6. Antibody responses (mean ± SEM, n=3) in mice infected with 
recombinant S. typhimurium x4064 (pDG-6). Sera were assayed for 
antibodies against B-hsp60, or ^4064 S.A. as described in Materials and 
Methods. Results are representative of two separate experiments. 
response to in vitro stimulation with B-hsp60. In all cases, 
splenocytes from vaccinated mice showed the highest stimulation 
indices when cultured in the presence of %4064 soluble antigen in vitro. 
All stimulation indices reported are at least 2 times higher than those 
obtained from non-vaccinated mice treated in parallel at each time 
point (data not shown). 
Cytokine secretion patterns 
Splenocytes derived from mice vaccinated with the strains x4064 
(pJE-3) (representing no B-hsp60 expression), x4064 (pDG-6) 
(representing low levels of B-hsp60 expression), and x4064 (pDG-4) 
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Figure 7. Antibody responses in recombinantSa/mone/Za infected mice 
(mean i^SEM, n=3) late during the course of infection. Non-infected 
control mice, and mice orally infected with 8 x10^ S. typhimurium 
X4064 (pDG-4), %4064 (pDG-6), or x4064 (pJE-3), were bled at days 35, 
64, or 84 post-infection, and serum from each mouse was analyzed for 
antibodies to B-hsp60 (A), or x4064 S.A.(B), as described in the 
Materials and Methods. 
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Figure 8. Blastogenic responses of recombinant S. typhimurium x4064-
vaccinated mice. Mice infected with S. typhimurium x4064 (pDG-4) (A), 
or S. typhimurium ^4064 (pDG-6) (B) were sacrificed on the indicated 
days, post infection. Single cell suspensions were prepared from 
spleens of these mice, and cultured in the presence or absence of B-
hsp60, or x4064 SA at 5 |ig per mL. Blastogenic stimulation was 
calculated as described in Materials & Methods. Results are expressed 
as mean ± SEM for groups of 3 mice (A), or 4 mice (B), per time point. 
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(representing moderate levels of B-hsp60 expression, also see Figure 
2) were tested for the secretion of the cytokines IFN-y, IL-4, and IL-10, 
following in vitro stimulation with various antigens. 
IFN-y production At day 34 post-infection, splenocytes from 
all vaccinated mice showed vigorous stimulation of IFN-y production in 
response to x4064 S.A., but not to B-hsp60 when cultured for 3 days in 
the presence of these antigens. (Figure 9). 
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hsp60 Q 
NO ANTIGEN 
interferon y (units per 10^ splenocytes) 
200 400 600 800 1000 1200 
Figure 9, Interferon gamma secretion by recombinant x4064-vaccinates 
at 34 days post-infection. Mice infected with ^4064 (pDG-4), ^4064 
(DG-6), or x4064 (pJE-3), and non-vaccinated mice were sacrificed at 
day 34 post infection. Single cell suspensions were prepared from 
spleens of these mice, and cultured in the presence of medium only, 
medium plus B-hsp60 (at 10 jxg per mL), or medium plus x4064 soluble 
antigens (at 10 ng per mL). After 3 days in culture supernatants were 
harvested and assayed for interferon-yby ELISA, as described in 
Materials & Methods. Results expressed as mean (shaded rectangles) ± 
SEM (clear rectangles) for 4 mice per group. 
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At day 64 post-infection, splenocytes from all vaccinated mice 
sliowed stimulation of IFN-y production in response to %4064 S.A., and 
B-hsp60 when cultured for 3 days in the presence of these antigens. 
(Figure 10).The splenocytes collected from mice at day 84 post­
infection showed very low responses to x4064 S.A., and no stimulation 
in response to B-hsp60, when cultured for 3 days in the presence of 
these respective antigens (data not shown). However, detectable 
stimulation of IFN-y was observed when the day 84 splenocytes were 
cultured for 5 days in the presence of x4064 S.A. or B-hsp60 (figure 
1 1 ) ,  
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Figure 10. Interferon gamma secretion by recombinant x4064 
vaccinates at 64 days post-infection. Mice infected with x4064 (pDG-
4), x4064 (DG-6), x4064 (pJE-3), and non-infected mice were 
sacrificed at day 64 post infection, and processed as described in 
Figure 9. 
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Figure 11. Interferon gamma secretion by recombinant x4064 
vaccinates at 84 days post-infection. Mice infected with 5c4064 (pDG-
4), %4064 (DG-6), %4064 (pJE-3), and non-infected mice were 
sacrificed at day 84 post infection, and processed as described in 
figure 9, except that the supernatants were harvested after 5 days in 
culture, as opposed to 3 days. 
a result consistent with the expected lag seen in the activation of a 
memory population of T cells [see ref. 119 for a recent review]. There 
were no statistically significant differences between the amounts of 
IFN-y secreted in response to B-hsp60 by splenocytes from the 3 groups 
of recombinant x4064 infected mice at day 34, day 64, or day 84 post­
infection. The fact that x4064 (pJE-3) vaccination elicited antigen 
specific IFN-y production upon stimulation with B-hsp60 (which this 
Salmonella strain does not express) is not surprising, and is most 
likely due to cross-stimulation of splenocytes sensitized to S. 
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typhimurium x4064's own endogenous hsp60, as a result of the high 
degree of homology that exists between heat shock proteins from 
diverse organisms. The stimulated secretion of IFN-y by splenocytes of 
vaccinated mice in response to B-hsp60 or x4064 soluble antigens was 
clearly an acquired response, since non-vaccinated control mice failed 
to produce IFN-y when stimulated under similar conditions. In vitro 
stimulation of splenocytes from all groups of experimental and control 
mice with another Brucella abortus derived E coll recombinant 
protein BCSP31 [35,40,60], and also purified S. typhimurium wild type 
LPS (purchased from Sigma, St. Louis, MO) failed to stimulate the 
secretion of IFN-yCdata not shown). A consistent observation was the 
secretion of higher concentrations of IFN-y in response to stimulation 
of the splenocytes from all groups of recombinant x4064 infected mice 
with ;c4064 soluble antigen, as compared to B-hsp60. It should be noted 
however that the quantities of IFN-y secreted by all the vaccinated 
mice in response to B-hsp60 at days 64 and 84 post-infection are in 
excess of the reported minimal concentrations of IFN-y required to 
stimulate bactericidal activity of macrophages in vitro [73], and to 
result in a significant reduction of splenic bacterial loads of Brucella 
abortus in vivo [76]. 
IL-4 production At days 34, 64, and 84 post-infection, in 
vitro stimulation of splenocytes from vaccinated and non-vaccinated 
groups of mice with B-hsp60, x4064 S.A. or S. typhimurium wild type 
LPS failed to elicit IL-4 production (less than 1 unit per 1 x 10^ 
splenocytes) as illustrated in Figures 12 through 14. In all cases. 
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Figure 12. IL-4 secretion by recombinant %4064 vaccinates at 34 days 
post-infection. Mice infected with x4064 (pDG-4), ^4064 (DG-6), or 
X4064 (pJE-3), as well as non-vaccinated mice were sacrificed at day 
34 post infection. Single cell suspensions were prepared from spleens 
of these mice, and cultured in the presence of medium only, medium 
plus B-hsp60 (at 10 |ig per mL), or medium plus x4064 soluble antigens 
(at 10 |ig per mL). After 3 days in culture supernatants were harvested 
and assayed for IL-4 by ELISA, as described in Materials & Methods. 
Results expressed as mean (shaded rectangles) ± SEM (clear rectangles) 
for 4 mice per group. 
the secreted amounts of IL-4 in response to B-hsp60, or %4064 S.A. 
were similar in splenocytes from vaccinated, as well as non-
vaccinated control mice treated in parallel (data not shown). This 
finding may explain the relatively long lag period seen in the rise of 
total immunoglobulin G responses against both B-hsp60 and x4064 S.A. 
when BALB/c mice were vaccinated with recombinant S. typhimurium 
x4064 (this experiment). However, it should be noted that IFN-yis 
itself capable of promoting antibody production and immunoglobulin 
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Figure 13. IL-4 secretion by recombinant ^4064 vaccinates at 64 days 
post-infection. Mice infected with x4064 (pDG-4), x4064 (DG-6), or 
%4064 (pJE-3), as well as non-infected mice were sacrificed at day 64 
post infection, and processed as described in figure 12. 
isotype switching [118], and could therefore be responsible for the 
humoral responses seen in these experiments against B-hsp60 and 
X4064S.A. 
IL-10 production At days 34, and 64, and 84, post-infection, 
in vitro stimulation of splenocytes from vaccinated mice with x4064 
S.A. resulted in stimulation of IL-10 production (Figures 15 throughl 7). 
Stimulation of splenocytes recovered from vaccinated mice also 
elicited IL-10 production in response to B-hsp60. Whereas little 
difference was seen in IL-10 secreted at day 34 in response to B-
hsp60, some differences in the amount of IL-10 secreted in response to 
B-hsp60 were observed between the groups of infected mice at both 64 
and 84 days post-infection. Splenocytes from %4064 (pDG-4) infected 
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Figure 14. IL-4 secretion by recombinant x4064 vaccinates at 84 days 
post-infection. Mice infected with x4064 (pDG-4), x4064 (DG-6), or 
%4064 (pJE-3), as well as non-infected mice were sacrificed at day 84 
post infection, and processed as described in figure 12, except that the 
supernatants were harvested after 5 days in culture, as opposed to 3 
days. 
mice secreted the most IL-10, followed by x4064 (pDG-6) and %4064 
(pJE-3), in decreasing order (Figures 16, 17). The antigen specific 
stimulation of IL-10 secretion was found to be less stringently 
controlled than the antigen specific stimulated secretion of IFN-y, in 
that a variety of antigens, including B-hsp60, ^4064 S.A, as well as S. 
typhimurium wild type LPS were all found to stimulate the secretion 
of low amounts of IL-10 from non-vaccinated mice (data not shown). 
This may be due to the fact that cell types other than T-lymphocytes 
are capable of IL-10 synthesis and secretion [56]. 
Cytolytic activity The ability of splenocytes from x4064 
vaccinates to mediate lysis of antigen pulsed cells was tested using 
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Figure 15. lnterleukin-10 secretion by x4064 vaccinates at 34 days 
post-infection. Mice infected with ^4064 (pDG-4), x4064 (DG-6), or 
x4064 (pJE-3), as well as non-vaccinated mice were sacrificed at day 
34 post infection. Single cell suspensions were prepared from spleens 
of these mice, and cultured in the presence of medium only, medium 
plus B-hsp60 (at 10 |ig per mL), or medium plus x4064 soluble antigens 
(at 10 |Lig per mL). After 3 days in culture supernatants were harvested 
and assayed for IL-10 by ELISA, as described in Materials & Methods. 
Results expressed as mean (shaded rectangles) ± SEM (clear rectangles) 
for 4 mice per group. 
vaccinated, as well as non-vaccinated mice, in response to B-hsp60. 
The levels of cytolytic activity correlated well with the relative 
amount of B-hsp60 originally delivered to the immune system; thus the 
highest level of cytolytic activity was seen in the case of x4064 (pDG-
4) vaccinates, and decreased for x4064 (pDG-6) vaccinates. Mice 
infected with ^4064 (pJE-3) showed the lowest level of cytolytic 
activity, and there was no apparent difference between this cytolytic 
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Figure 16. lnterleukin-10 secretion by recombinant x4064 vaccinates 
at 64 days post-infection. Mice infected with x4064 (pDG-4), %4064 
(DG-6), or 5c4064 (pJE-3), as well as non-infected mice were sacrificed 
at day 84 post infection, and processed as described in figure 15. 
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Figure 17. IL-10 secretion by recombinant x4064 vaccinates at 84 days 
post-infection. Mice infected with x4064 (pDG-4), ^4064 (DG-6), or 
x4064 (pJE-3), as well as non-infected mice were sacrificed at day 84 
post infection, and processed as described in figure 15, except that the 
supernatants were harvested after 5 days in culture, as opposed to 3 
days. 
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Figure 18. Cytotoxic activity of splenocytes from recombinant x4064 
vaccinates. Mice infected with x4064 (pDG-4), x4064 (DG-6), or x4064 
(pJE-3), as well as non-vaccinated mice were sacrificed at day 84 post 
infection. Single cell suspensions were prepared from spleens of these 
mice, and cultured in the presence of medium plus B-hsp60 at 10 |ig per 
mL for 5 days. Cytolytic activity against J774 target cells was 
measured by release of LDH, as described in Materials and Methods. 
Results shown correspond to an effector to target ratio of 2:1 and are 
expressed as means of triplicate wells. 
activity when compared to that of splenocytes collected from non-
vaccinated mice. The results of cytolytic activity obtained using the 
release of lactate dehydrogenase (LDH) as an index of cytolysis of 
target cells (figure 18) was confirmed cytologically, where the 
o 
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Figure 19. Cytolytic activity of recombinant ^4064 vaccinates. 
Splenocytes from non-infected (CTRL) or infected mice (x4064), 
treated as described in figure 18 were cultured with identical numbers 
of J774 target cells in medium containing 20 ^ig per mL B-hsp60, at the 
indicated effector to target-cell ratios. J774 cells were harvested 
after 72 hours, and analyzed by flow cytometry for total number of 
dead cells in each experimental culture. Results shown are 
representative of two separate experiments. 
accumulation of dead J774 target cells in the various experimental 
cultures in response to B-hsp60 stimulation (Figure 19), or %4064 S.A. 
(Figure 20) were quantitated by flow cytometry. Reliable estimates of 
the numbers of dead cells were made by taking advantage of the 
decrease in overall size (forward light scatter), and granularity (side 
light scatter) of dead J774 cells. This protocol was standardized for 
J774 cells in earlier and dead cells was confirmed by the ability of live 
cells to exclude the cytoplasmic membrane-impermiant fluorescent 
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Figure 20. Cytolytic activity of %4064 vaccinates. Splenocytes from 
non-infected (CTRL) and infected mice (%4064), treated as described in 
figure 18 were incubated with identical numbers of J774 target in 
medium containing 20 |j,g per mL x4064 (JE-3) soluble antigen, at the 
indicated effector to target-cell ratios, cells for 72 hours. J774 cells 
were harvested and analyzed by flow cytometry for total number of 
dead cells accumulated in each experimental culture. Results shown are 
representative of two such experiments. 
nucleic acid dye,propidium iodide. Cytolytic activity of the splenocytes 
was tested late in the infection because it had been previously shown 
in the case of murine mycobacteriosis, that a low level of antigen 
specific cytolytic activity, mediated by CD4+ T cells was demonstrable 
relatively late in the course of the mycobacterial infection [44]. 
Cytotoxic T-lymphocytes of the CD8+ phenotype have previously been 
demonstrated, to arise during the course of murine salmonellosis [116]. 
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DISCUSSION 
As a group, intracellular bacterial pathogens present major 
conceptual and experimental challenges to the fields of immunology and 
microbial molecular genetics. For each pathogen, there exists a very 
poor understanding of how the microorganism is able to survive and 
multiply in the hostile environment of the animal body. For many of 
these same organisms, it has proven difficult to develop vaccines 
which provide lasting protection against re infection. Organisms 
included in this latter category include Brucella abortus, 
Mycobacterium tuberculosis, Mycobacterium leprae, and Salmonella 
typhi. Each of these organisms can and does live and replicate within 
macrophages inside the living host, each can cause chronic disease, and 
for each, the best (though imperfect) existing vaccine is based on 
infection with a live attenuated bacterial strain. Many experiments 
suggest that for these organisms, only a prolonged infection can lead to 
protective immunity. In each case, a molecular understanding of how 
these organisms can survive and replicate in the macrophage, an 
understanding of how they are able to evade immune surveillance, and 
an immunological understanding of why prolonged infection is required 
to produce protective immunity and why this immunity is frequently 
imperfect, is lacking. 
Live carrier vaccination would seem to be a powerful tool for 
studying all of these issues. With this system, the heterologous (test) 
antigen is separated from the rest of the biological activities normally 
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associated with the pathogen which should allow a clearer 
interpretation of results, and a properly chosen host and carrier system 
can provide both intracellular expression and prolonged infection of the 
host. We chose, as the carrier, S. typhimurium x4064 which is 
attenuated by deletions in both the cya and crp genes and the BALB/c 
mouse as the test animal model. As the test antigen, we chose the 
Brucella abortus heat shock protein 60 (B-hsp60), in part, because 
reports in the literature documented the strong immunogenicity of 
other members of this protein family derived from other pathogens. 
There are many potential questions which might be addressed by this 
system. Some examples of these are: 1. Are the immune responses 
generated by the mouse against a single antigen derived from Brucella 
abortus sufficient to provide protection against B. abortus infection 
when the antigen is delivered in the context of a prolonged (non-
Brucella) bacterial infection? 2. Does B. abortus modulate the nature 
of the immune response differently than S. typhimurium during the 
course of infection? 3. Do multiple antigens provide better protection 
than a single antigen? 4. Is the immunity generated in this system 
against different antigens qualitatively similar or different? 
The first aim of this study was to determine whether or not B-
hsp60 was a suitable test antigen. The criteria for a suitable test 
antigen was that when mice were infected with S. typhimurium x4064 
expressing B-hsp60, both humoral and cellular immunity would develop 
to the protein during the course of the Salmonella infection. The 
second aim was to characterize relevant aspects of the immune 
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response during the course of the infection; and the third aim was to 
determine the effect of expressing different amounts of the test 
antigen in the carrier salmonellae on measured aspects of immunity. 
This later aim is of practical interest because expression of proteins 
in heterologous organisms requires the selection of a promoter, and 
high expression is frequently deleterious to the vaccine strain. 
The results of this study have adequately demonstrated that B-
hsp60 was delivered to the immune system of mice by oral vaccination 
with recombinant attenuated S. typhimurium x4064 expressing the 
protein, and that parameters of both humoral and cellular immunity 
were generated under the appropriate conditions. Differences in the 
quality of immune responses were seen between %4064 (pDG-6), (the 
strain with low constitutive expression of B-hsp60), and ^4064 (pDG-
4), (the strain with moderate constitutive expression of B-hsp60). This 
was reflected in marked differences in humoral antibody production 
seen at days 34 through 84 post-infection (high in the case %4064 
(pDG-4) infected mice, and none in the case of %4064 (pDG-6) infected 
mice). Although the humoral antibody responses were negligible in 
%4064 (pDG-6) infected mice, the blastogenic, as well as cytotoxic 
responses due to stimulation with B-hsp60 in vitro support the notion 
that the %4064 (pDG-6) infected mice were exposed to an immunogenic 
quantity of B-hsp60, even though this was insufficient to elicit a 
significant humoral response. The ability of foreign {non-Salmonella ) 
antigens to trigger specific immune responses, such as antigen specific 
cytotoxic T cells, in the absence of an apparent antibody response has 
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been reported in at least 2 different studies [120,121 ] and is 
reaffirmed in this study. 
The results of the stimulated secretion of lymphokines are at 
first glance strange. The pattern of secreted lymphokines in response 
to in wtro stimulation of splenocytes from recombinant x4064 (pDG-6) 
infected mice with either B-hsp60, or x4064 soluble antigen revealed 
similar patterns of T cell stimulation, characterized by substantial 
quantities of interferon gamma and IL-10, but no secretion of IL-4. The 
presence of interferon gamma, in the absence of IL-4 is suggestive of a 
TH1 type T cell response. Although the presence of IL-10 is suggestive 
of a TH2 type T cell response, a recent report suggests that IL-10 
levels are elevated in certain types of TH1 response [120]. Whereas the 
importance of interferon gamma in immunity against intracellular 
pathogens is well documented, the currently accepted models do not 
include IL-10 as a component of a protective immune response against 
intracellular bacteria. There are at least two explanations for the 
presence of IL-10 in the supernatants of antigen stimulated 
splenocytes from infected mice: one is that IL-10 constitutes part of a 
down-regulatory host reaction to a highly activated inflammatory 
state, following resolution of the x4064 primary infection, and the 
other possibility is that IL-10 is a component of a protective response 
against S. typhimurium x4064 in particular, and intracellular bacteria 
in general. IL-10 was originally discovered and characterized by its 
suppression of inflammatory responses, including inhibition of TH1 
cytokine production [122] and inhibition of the production of reactive 
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nitrogen intermediates by macrophages[123]. While these reports favor 
IL-10 production as down-regulatory of the inflammatory state, a 
fairly strong case can be made for IL-10 production as a component of 
the protective response, although this is supported only by 
circumstantial evidence. IL-10 has been shown to be a cytotoxic T cell 
differentiation factor that markedly increases the clonal size, and 
lytic potential of cytotoxic T cell precursors [124]. This report is 
intriguing for a number of reasons. Brucella abortus has been shown to 
be capable of infecting a variety of phagocytic, as well as non-
phagocytic cell types [27]. Because the vast majority of non­
professional phagocytes lack a full repertory of bactericidal 
mechanisms, such infected cells may provide a safe haven for the 
bacteria. In such a situation, cytolytic cells capable of recognizing 
infected cells could come into play, lysing the infected targets to 
release the bacteria which could then be more effectively dealt with by 
circulating professional phagocytes. In support of this, the generation 
of antigen specific cytolytic T cells has been demonstrated during the 
course of infection for several intracellular bacterial species [44,114-
116,120]. Furthermore, it has been recently demonstrated that 
bacterial antigens can access the MHC class I antigen processing 
pathway for effective in vivo priming of CD8+ cytotoxic T cells [125]. 
It is interesting that there is no evidence in the data presented 
here for a TH1 to TH2 switch during the course of the live carrier 
infection. Such a switch should be manifested by an increase in IL-4 
and IL-10 and a decrease in IFN-y during the course of the infection. It 
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is also interesting to speculate on whether or not the unusual cytokine 
profile of high IFN-y, low IL-4, and high IL-10 observed in these 
experiments is a Salmonella specific response. In one recent report, 
immunization of BALB/c mice with killed Brucella abortus was 
consistently found to stimulate the elevated expression of genes coding 
for IL-10 and IFN-ybut not of the genes coding for IL-4 and IL-5 by 
CD4+ T cells [120]. Because comparable data does not exist for live 
infections with other intracellular bacterial parasites, we cannot say 
at this time whether or not this profile is the typical response to 
prolonged intracellular infections or if it is specific to certain 
subclasses of infections. 
In a number of instances, there were tantalizing, though not 
always statistically significant, differences in the responses to B-
hsp60 when comparing infection with x4064 (pDG4) with x4064 (pDG6) 
[for example, see Figures 5, 6, 9, 10, 11, 16, 17, and 18]. These 
differences suggest that subtle differences in the immune response 
which are dictated by the concentration of the antigen within the 
pathogen itself. The significance of these differences is not presently 
understood. It remains possible that x4064 (pDG6) is actually the 
better vaccine, and that over expression of an antigen may be counter 
productive by inducing tolerance, as has been reported for vaccination 
experiments using fractionated components of Brucella abortus [35]. 
From the data collected in this study it is not possible to predict 
whether or not vaccination of mice with x4064 (pDG4) or x4064 
(pDG6) would be protective against brucellosis because it is not known 
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precisely what aspects of immunity are required for protection against 
Brucella abortus infection. It is encouraging that for all the parameters 
measured, the response to B-hsp60 is similar, though often lower, to 
the response to total Salmonella soluble antigen (S.A.). Others have 
shown that infection of BALB/c mice with x4064 produces a high 
degree of protection against subsequent infection with the virulent 
parental strain of x4064 [117]. Thus, it could be argued that the 
qualitatively similar immunity to B-hsp60 might be provide protection 
against Brucella abortus infection. It should be pointed out that not all 
antigens stimulate immune responses qualitatively similar to those 
elicited against %4064 S.A. in this system. In an earlier paper, Stabel et 
al [40] demonstrated that another Brucella protein, BCSP31, is a strong 
humoral antigen but produces no detectable cellular response when 
delivered to the mouse by the same live carrier vaccination protocol 
used here. 
In conclusion, this study has demonstrated that the immune 
response to B-hsp60 when presented to the immune system in the 
context of a live infection in BALB/c mice was qualitatively similar to 
the immune response generated against Salmonella typhlmurlum x4064 
itself. A study has been undertaken to assess the protective effects of 
this vaccination scheme against a subsequent infection with Brucella 
abortus. 
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APPENDIX. Eri/ce//a aiborti/s flrro E DNA SEQUENCE 
. . .-35 . . 
GCTGTTCGCGCAAAAACGCCAGCCTGAACGGCAATCCTCCTTGACAAAAAAACATtGCGG 60 
-10 . 
CTTCTATCTCAAGAACCAGGTTARCACTCGGACGAATAGAGTGCTAACAGCGGGCCATTC 120 
CGGTCCGCGTAACAGGGTTCAACGTCTATAACACCAAGGGTTATACCATGGCTGATATCA 180 
MetAlaAspIleL 
AGTTCCGCCCGCTTCATGACCGCGTCGTCGTTCGCCGCGTCGAATCGGAAGCCAAGACTG 240 
ysPheArgProLeuHisAspArgValValValArgArgValGluSerGluAlaLysThrA 
CCGGCGGCATCATCATCCCTGACACTGCCAAGGAAAAGCCGCAGGAAGGCGAAGTCGTTG 300 
laGlyGlyllellelleProAspThrAlaLysGluLysProGlnGluGlyGluValValA 
CAGCCGGTgcTGGCGCTCGTGACGAAGCTGGCAAGCTGGTTCCGCTGGATGTCAAGGCTG 360 
laAlaGlyAlaGlyAlaArgAspGluAlaGlyLysLeuValProLeuAspValLysAlaG 
GCGACCGCGTTCTGTTCGGCAAGTGGTCGGGCACCGAAGTCAAGATCGGCGGCGAAGACC 420 
lyAspArgValLeuPheGlyLysTrpSerGlyThrGluValLysIleGlyGlyGluAspL 
TGCTGATCATGAAGGAATCCGACATTCTGGGTATTGTCGGCTAAAAAATTCCTTTTGCGT 480 
euLeuIleMetLysGluSerAspIleLeuGlylleValGlyEnd 
TGCTTCACGCAACCAGAATTCCATTCACAGTACAACATTTACAAATCTGACCGGGATATT 540 
CCCAGGAGAGTAAAATGGCTGCAAAAGACGTAAAATTCGGCCGcACTGCGCGCGAAAAGA 600 
MetAlaAlaLysAspValLysPheGlyArgThrAlaArgGluLysM 
TGCTGCGCGGCGTCGATATCCTCGCTGACGCTGTTAAGGTCACGCTCGGCCCGAAGGGCC 660 
etLeuArgGlyValAspIleLeuAlaAspAlaValLysValThrLeuGlyProLysGlyA 
GCAATGTCGTTATCGAGAAGTCCTTCGGCGCTCCGCGCATCACCAAGGACGGCGTTTCGG 720 
rgAsnValVallleGluLysSerPheGlyAlaProArglleThrLysAspGlyValSerV 
TCGCCAAGGAAGTCGAACTGGAAGACAAGTTTGAAAACATGGGCGCACAGATGCTGCGCG 780 
alAlaLysGluValGluLeuGluAspLysPheGluAsnMetGlyAlaGlnMetLeuArgG 
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AAGTGGCTTCCAAGACCAACGATACTGCCGGTGACgGCACCACGACCGCGACCGTTCTCG 840 
luValAlaSerLysThrAsnAspThrAlaGlyAspGlyThrThrThrAlaThrValLeuG 
GTCAGGCCATCGTTCAGGAAGGCGCCAAGGCCGTTGCCGCTGGCATGAACCCGATGGACC 900 
lyGlnAlalleValGlnGluGlyAlaLysAlaValAlaAlaGlyMetAsnProMetAspL 
TGAAGCGCGGCATCGACCTCGCTGTCAACGAAGTTGTGGCTGAGCTGCTGAAGAAGGCCA 960 
euLysArgGlylleAspLeuAlaValAsnGluValValAlaGluLeuLeuLysLysAlaL 
AAAAGATCAACACTTCGGAAGAAGTTGCCCAGGTTGGCACCATCTCTGCCAAcgcCGAAg 1020 
ysLysIleAsnThrSerGluGluValAlaGlnValGlyThrlleSerAlaAsnAlaGluA 
CCGAAATCGGCAAGATGATCGCCGAAGCGATGCAGAAGGTCGGCAACGAAGGCGTCATCA 1080 
laGluIleGlyLysMetlleAlaGluAlaMetGlnLysValGlyAsnGluGlyVallleT 
CGGTTGAAGAAGCCAAGACCGCCGAAACCGAACTCGAAGTCGTCGAAGGCATGCAGTTCG 1140 
hrValGluGluAlaLysThrAlaGluThrGluLeuGluValValGluGlyMetGlnPheA 
ACCGCGGCTACCTGTCGCCTTACTTCGTCACCAACCCTGAAAAGATGGTTGCTGACCTCG 1200 
spArgGlyTyrLeuSerProTyrPheValThrAsnProGluLysMetValAlaAspLeuG 
AAGACGCCTACATCCTTCTGCACGAAAAGAAGCTCTCGAACCTTCAGGCTCTCCTGCCGG 1260 
luAspAlaTyrlleLeuLeuHisGluLysLysLeuSerAsnLeuGlnAlaLeuLeuProV 
TTCTCGAAGCTGTCGTCCAGACCTCCAAGCCGCTTCTCATCATTGCTGAAGACGTCGAAG 1320 
alLeuGluAlaValValGlnThrSerLysProLeuLeuIlelleAlaGluAspValGluG 
GCGAAGCTCTTGCAACGCTCGTCGTCAACAAGCTGCGCGGCGGCCTGAAGATTGCTGCCG 1380 
lyGluAlaLeuAlaThrLeuValValAsnLysLeuArgGlyGlyLeuLysIleAlaAlaV 
TCAAGGCTCCGGGCTTCGGCGATCGCCGCAAGGCCATGCTCGAAGACATCGCGATCCTCA 1440 
alLysAlaProGlyPheGlyAspArgArgLysAlaMetLeuGluAspIleAlalleLeuT 
CTGGCGGTCAGGTCATCTCCGAAGACCTCGGCATCAAGCTTGAAAGCGTTACGCTCGACA 1500 
hrGlyGlyGlnVallleSerGluAspLeuGlylleLysLeuGluSerValThrLeuAspM 
TGCTGGGCCGCGCCAAGAAGGTTTCGATCTCCAAGGAAAACACGACGATCCTTGACGGTG 1560 
etLeuGlyArgAlaLysLysValSerlleSerLysGluAsnThrThrlleLeuAspGlyA 
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CAGGCCAGAAGGCCGAAATCGACGCTCGCGTTGGCCAGATCAAGCAGCAGATCGAAGAAA 1620 
laGlyGlnLysAlaGluIleAspAlaArgValGlyGlnlleLysGlnGlnlleGluGluT 
CCACTTCGGACTACGACCGTGAAAAGCTTCAGGAACGTCTTGCCAAGCTCGCTGGCGGCG 168 0 
hrThrSerAspTyrAspArgGluLysLeuGlnGluArgLeuAlaLysLeuAlaGlyGlyV 
TTGCCGTGATCCGCGTCGGCGgTGCAACGGAAGTTGAAGTGAAGGAAAAGAAGGACCGCG 1740 
alAlaVallleArgValGlyGlyAlaThrGluValGluValLysGluLysLysAspArgV 
TTGACGACGCCCTGAACGCAACCCGGGCTGCGgTTGAAGAAGGTATCGTTGCCGGCGGCG 1800 
alAspAspAlaLeuAsnAlaThrArgAlaAlaValGluGluGlylleValAlaGlyGlyG 
GCACCGcCCTGCTCCGCGCTTGGACCAAGATCACCGCAAAGGGTGTGAATGCCGACCAGG 1860 
lyThrAlaLeuLeuArgAlaSerThrLysIleThrAlaLysGlyValAsnAlaAspGlnG 
AAGCTGGCATCAACATCGTTCGTCGCGCGATCCAGGCTCCGGCCCGCCAGATCACGACCA 1920 
luAlaGlylleAsnlleValArgArgAlalleGlnAlaProAlaArgGlnlleThrThrA 
ATGCCGGTGAAGAAGCTTCGGTAATCGTTGGCAAGATCCTCGAAAACACGTCCGAAACCT 1980 
snAlaGlyGluGluAlaSerVallleValGlyLysIleLeuGluAsnThrSerGluThrP 
TCGGCTACAACACGGCCAATGGCGAATATGGCGACCTGATCTCGCTCGGCATTGTTGACC 2040 
heGlyTyrAsnThrAlaAsnGlyGluTyrGlyAspLeuIleSerLeuGlylleValAspP 
CGGTCAAGGTTGTCCGCACGGCTCTGCAGAACGCAGCTTCGGTTGCCGGCCTGCTGATCA 2100 
roValLysValValArgThrAlaLeuGlnAsnAlaAlaSerValAlaGlyLeuLeuIleT 
CGACGGAAGCAATGATCGCCGAACTGCCGAAGAAGGACGCAGCTCCGGCTGGCATGCCTG 2160 
hrThrGluAlaMetlleAlaGluLeuProLysLysAspAlaAlaProAlaGlyMetProG 
GCGGTATGGGTGGCATGGGCGGCATGGACTTCTAAGAAGTCCATAAAGCTCGCCCATGAA 2220 
lyGlyMetGlyGlyMetGlyGlyMetAspPheEnd 
CTAAATGCCTGCGCCGCAAAgcggcgcgggggcGGCATGGACTTCCAAGAAGTCCATGCC 2280 
ACCGCAGGACAGGCGAGAAAGCGTGCCCCACTGCGACCAGAAATTTAAAAACCTCCGGTT 2340 
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CCCGCCGGAGGTTTTTTATTCGCTAAAATAAATACCCATACTGGTGACATtCACGGGTGT 2400 
